Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Phase 2RecruitingNCT07167160

Women's Hospital School Of Medicine Zhejiang University59 enrolled

Overview

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cervical Cancer Immunochemotherapy

Interventions

Camrelizumab combined with chemotherapyDRUG

Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery; 2. Positive PD-L1 expression; 3. ECOG score ≤1 Exclusion Criteria: 1. Positive parametrium or surgical margin; 2. Incomplete radical surgery; 3. Residual target lesions; 4. Active autoimmune disease or autoimmune disease requiring systemic treatment; 5. Previous treatment with immune checkpoint inhibitors.

Locations (1)

Women's Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

3-year disease-free survival rate

Time frame: from enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 100 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.